
Ovid Therapeutics (OVID) Stock Forecast & Price Target
Ovid Therapeutics (OVID) Analyst Ratings
Bulls say
Ovid Therapeutics is attractive because its lead asset OV329 targets a clinically validated epilepsy mechanism, GABA-AT inhibition, but is engineered to avoid vigabatrin’s retinal toxicity and gram-scale dosing burden, with Ph1 data across 68 volunteers showing clean ophthalmology and stronger cortical inhibition than historical vigabatrin at 400-600× lower dose. The investment case is further supported by large unmet need, since 30-40% of the ~3M US epilepsy population continues to seize despite 2+ AEDs, while OV329 could address refractory focal onset seizures and pediatric DEE settings where vigabatrin precedent suggests meaningful commercial opportunity. In addition, Ovid’s KCC2 portfolio adds first-in-class optionality in psychosis, and the balance sheet of $169.8M cash as of June 30, 2026 is expected to fund operations into 2029.
Bears say
Ovid Therapeutics is viewed negatively because its value proposition is highly contingent on a fragile, early-stage epilepsy pipeline that faces major risks from clinical failure, safety or tolerability issues, regulatory delays, and potential new competitors. The bear case suggests the company is effectively a cash shell, with only FY27 net cash and exercise proceeds supporting the $0.58 bear value, while the KCC2 pipeline (OV4071) is assigned no value in any case. With a 20% probability of success across all three indications and a 12% discount rate, the analysis implies that financing risk remains elevated until cash flow turns positive.
This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction
Start investing in Ovid Therapeutics (OVID)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ovid Therapeutics (OVID) Forecast
Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction
Start investing in Ovid Therapeutics (OVID)
Order type
Buy in
Order amount
Est. shares
0 shares